Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
Acumen Pharmaceuticals (NASDAQ: ABOS) will present two studies at the Alzheimer's Association International Conference (AAIC® 2025) in Toronto from July 27-31, 2025. The first presentation will analyze cost savings from using pTau217 as a screening tool in their Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's disease. The second study will examine sabirnetug's selectivity for Aβ oligomers compared to other treatments.
The presentations will be delivered as posters on July 28 and 29, featuring findings that demonstrate the company's progress in trial design efficiency and the drug's targeted therapeutic approach. Dr. Todd Feaster and Dr. Erika N. Cline will present the respective studies, focusing on biomarker-driven screening and drug selectivity analysis.
Acumen Pharmaceuticals (NASDAQ: ABOS) presenterà due studi alla Conferenza Internazionale dell'Associazione Alzheimer (AAIC® 2025) a Toronto dal 27 al 31 luglio 2025. La prima presentazione analizzerà i risparmi sui costi derivanti dall'uso del pTau217 come strumento di screening nel loro studio di Fase 2 ALTITUDE-AD sul sabirnetug per l'Alzheimer precoce. Il secondo studio esaminerà la selettività del sabirnetug verso gli oligomeri Aβ rispetto ad altri trattamenti.
Le presentazioni saranno esposte sotto forma di poster il 28 e 29 luglio, mostrando risultati che evidenziano i progressi dell'azienda nell'efficienza della progettazione degli studi e nell'approccio terapeutico mirato del farmaco. I dottori Todd Feaster ed Erika N. Cline presenteranno rispettivamente gli studi, concentrandosi sullo screening basato su biomarcatori e sull'analisi della selettività del farmaco.
Acumen Pharmaceuticals (NASDAQ: ABOS) presentará dos estudios en la Conferencia Internacional de la Asociación de Alzheimer (AAIC® 2025) en Toronto del 27 al 31 de julio de 2025. La primera presentación analizará los ahorros en costos derivados del uso de pTau217 como herramienta de cribado en su ensayo de Fase 2 ALTITUDE-AD con sabirnetug para la enfermedad de Alzheimer temprana. El segundo estudio examinará la selectividad de sabirnetug hacia los oligómeros Aβ en comparación con otros tratamientos.
Las presentaciones se entregarán en formato de póster los días 28 y 29 de julio, mostrando hallazgos que demuestran el progreso de la compañía en la eficiencia del diseño del ensayo y el enfoque terapéutico específico del medicamento. Los doctores Todd Feaster y Erika N. Cline presentarán los respectivos estudios, enfocándose en el cribado basado en biomarcadores y el análisis de selectividad del fármaco.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 2025년 7월 27일부터 31일까지 토론토에서 열리는 알츠하이머 협회 국제 학술대회(AAIC® 2025)에서 두 가지 연구를 발표할 예정입니다. 첫 번째 발표는 초기 알츠하이머병 치료를 위한 sabirnetug의 2상 ALTITUDE-AD 임상시험에서 선별 도구로서 pTau217 사용에 따른 비용 절감을 분석합니다. 두 번째 연구는 sabirnetug가 다른 치료제와 비교하여 Aβ 올리고머에 대한 선택성을 조사합니다.
발표는 7월 28일과 29일 포스터 형식으로 진행되며, 임상시험 설계 효율성과 약물의 표적 치료 접근법에서 회사의 진전을 보여주는 결과를 담고 있습니다. Todd Feaster 박사와 Erika N. Cline 박사가 각각 생체표지자 기반 선별과 약물 선택성 분석에 관한 연구를 발표할 예정입니다.
Acumen Pharmaceuticals (NASDAQ : ABOS) présentera deux études lors de la Conférence Internationale de l'Association Alzheimer (AAIC® 2025) à Toronto, du 27 au 31 juillet 2025. La première présentation analysera les économies de coûts liées à l'utilisation du pTau217 comme outil de dépistage dans leur essai de phase 2 ALTITUDE-AD sur le sabirnetug pour la maladie d'Alzheimer précoce. La deuxième étude examinera la sélectivité du sabirnetug pour les oligomères Aβ comparée à d'autres traitements.
Les présentations seront exposées sous forme de posters les 28 et 29 juillet, présentant des résultats démontrant les progrès de l'entreprise en matière d'efficacité de la conception des essais et de l'approche thérapeutique ciblée du médicament. Les Drs Todd Feaster et Erika N. Cline présenteront respectivement les études, en se concentrant sur le dépistage basé sur les biomarqueurs et l'analyse de la sélectivité du médicament.
Acumen Pharmaceuticals (NASDAQ: ABOS) wird auf der Alzheimer's Association International Conference (AAIC® 2025) in Toronto vom 27. bis 31. Juli 2025 zwei Studien vorstellen. Die erste Präsentation analysiert Kosteneinsparungen durch den Einsatz von pTau217 als Screening-Instrument in ihrer Phase-2-ALTITUDE-AD-Studie mit Sabirnetug bei früher Alzheimer-Krankheit. Die zweite Studie untersucht die Selektivität von Sabirnetug gegenüber Aβ-Oligomeren im Vergleich zu anderen Behandlungen.
Die Präsentationen werden am 28. und 29. Juli als Poster vorgestellt und zeigen Ergebnisse, die den Fortschritt des Unternehmens bei der Effizienz der Studiengestaltung und dem gezielten therapeutischen Ansatz des Medikaments belegen. Dr. Todd Feaster und Dr. Erika N. Cline werden die jeweiligen Studien vorstellen, mit Fokus auf biomarkerbasiertes Screening und Analyse der Medikamentenselektivität.
- None.
- None.
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.
Acumen’s presentation details are as follows:
Topic: ALTITUDE-AD: Cost Savings Using a pTau217 Screening Assay in an Ongoing Phase 2 Study of Sabirnetug in Early Alzheimer's Disease
- Date/Time: Monday, July 28, 7:30 a.m. - 4:15 p.m. EDT
- Format: Poster Presentation
- Session: Drug Development: Human
- Presenting Author: Todd Feaster, Psy.D., Senior Clinical Research Scientist, Acumen Pharmaceuticals
Topic: Sabirnetug selectivity for Aβ oligomers over monomers compared to recombinant lecanemab and aducanumab
- Date/Time: Tuesday, July 29, 7:30 a.m. - 4:15 p.m. EDT
- Format: Poster Presentation
- Session: Drug Development: Human
- Presenting Author: Erika N. Cline, Ph.D., Manager, Bioanalytical Methods, Acumen Pharmaceuticals
“Our presentation at AAIC highlight how combining biomarker-driven screening with a targeted therapeutic like sabirnetug represents meaningful progress in trial designs and drug development for Alzheimer’s disease,” said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. “We look forward to sharing these findings at AAIC, which reinforce both sabirnetug's distinct selectivity for toxic amyloid beta oligomers as well as our approach to making clinical trials more patient-centric and efficient.”
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “potential,” “will” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the therapeutic potential and potential clinical efficacy of Acumen’s product candidate, sabirnetug (ACU193). These statements are based upon the current beliefs and expectations of Acumen’s management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
Jon Yu
ICR Healthcare
AcumenPR@icrhealthcare.com
FAQ
When and where will Acumen Pharmaceuticals (NASDAQ: ABOS) present at AAIC 2025?
What will Acumen Pharmaceuticals present about sabirnetug at AAIC 2025?
Who are the presenting authors for Acumen's AAIC 2025 studies?
What is the format of Acumen's presentations at AAIC 2025?
